Abstract
Objectives: To determine efficacy of sofosbuvir and daclatasvir in the treatment
of chronic hepatitis C infection. Study Design: Experimental study. Setting: Hepatitis Clinic,
Sheikh Zayed Medical College/Hospital, Rahim Yar Khan. Period: June to December 2018.
Material & Methods: Five hundred patients having chronic hepatitis C infection including those
with compensated cirrhosis were included in the study. They were given sofosbuvir 400 mg
daily and daclatasvir 60 mg daily. Weight based ribavirin was added if patient has evidence of
cirrhosis. Treatment duration was 12 weeks for non-cirrhotic and 24 weeks for cirrhotics. End
of treatment response (ETR) was recorded. Results: Mean age of the included patients was
41±11.69 with range from 8 to 82 years, while 217 (43.4 %) patients were male and 283 (56.6 %)
were female. Cirrhosis was present in 59 (11.8 %) patients; among these 35.6 % were in Child
A and 64.4 % in early Child B. End of treatment response occurred in 491 (98.2 %) patients
and there was no significant difference in ETR between male and female patients, and between
cirrhotic and non-cirrhotic. Similarly, there was no significant difference in age between those
having ETR and those having no ETR. Fatigue was experienced by 13.2 % and headache by
4.2 % patients. Conclusion: The combination of sofosbuvir and daclatasvir has high response
rate in chronic hepatitis C patients of our population.
Irfan Ahmad, Ghulam Abbas, Muhammad Israr ul Haq. (2020) Response to combination of sofosbuvir and daclatasvir in chronic hepatitis C infection., The Professional Medical Journal, Volume 27, Issue 12.
-
Views
636 -
Downloads
43
